- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Eribulin Elicits Survival Advantage in Phase III Sarcoma Study
May 31st 2015, 4:14pm
Treatment with eribulin (Halaven) improved overall survival by 2 months compared with dacarbazine in patients with advanced leiomyosarcoma and adipocytic sarcoma.
Survivors of Childhood Cancers Living Longer Due to Improvements in Care and Follow-up
May 31st 2015, 3:46pm
Over the past 30 years, survivors of childhood cancers have become less likely to die of illnesses caused by their treatment, such as new malignancies or cardiac or lung disease.
Preventive Neck Lymph Node Surgery Should Become Standard of Care in Early Oral Cancer
May 31st 2015, 2:34pm
Elective neck dissection performed at the same time patients have surgery for early-stage, node-negative, oral squamous cell cancer significantly improved overall survival and reduced the risk of death and recurrence when compared with a watchful waiting approach.
Whole Brain Radiation More Harmful Than Beneficial for Small Brain Metastases
May 31st 2015, 2:30pm
Patients with small brain metastases from other tumor types should not routinely receive adjuvant whole brain radiation therapy (WBRT), according to a study that showed the treatment dramatically increases the incidence of cognitive decline without improving survival outcomes.
Numerous NSCLC Studies Offer Optimism for New Therapies
May 31st 2015, 2:26pm
Novel targeted therapies against ALK, BRAF, and RET have demonstrated promising outcomes in molecularly-defined patients with non-small cell lung cancer.
Frontline Nivolumab Regimens Significantly Improve PFS Versus Ipilimumab in Melanoma
May 31st 2015, 1:48pm
Frontline nivolumab as monotherapy and in combination with ipilimumab more than doubled progression-free survival versus ipilimumab alone in patients with advanced melanoma.
Study Disputes Lymph Node Removal Standard in Melanoma
May 31st 2015, 10:31am
Patients with melanoma who are found to have micrometastases after an initial positive sentinel node biopsy can safely forgo a complete lymph node dissection, thus avoiding the risk of debilitating adverse events from the surgery.
Atezolizumab Doubles OS in PD-L1-Positive NSCLC
May 31st 2015, 8:52am
Treatment with atezolizumab doubled overall survival compared with docetaxel in previously treated patients with PD-L1-positive squamous and non-squamous non-small cell lung cancer.
MEDI4736, Tremelimumab Combo Active in Pretreated NSCLC
May 31st 2015, 8:46am
An immunotherapy combination demonstrated "high levels of clinical activity" in previously treated non-small cell lung cancer across a range of doses.
Anastrozole Shows Preventive Advantages Over Tamoxifen After DCIS
May 31st 2015, 5:17am
The first study to compare the efficacy and safety of tamoxifen versus anastrozole in women treated for ductal carcinoma in situ suggests that anastrozole may be the better choice for preventing the escalation of DCIS into invasive cancer.
Dr. Jeffrey Jones on Efficacy of Idelalisib/Ofatumumab Combination in CLL
May 31st 2015, 5:07am
Jeffrey Jones, MD, MPH, Assistant Professor of Internal Medicine and section head of the Chronic Lymphocytic Leukemia (CLL) research program at Ohio State University, discusses the results of a phase III randomized, controlled study evaluating idelalisib (Zydelig) in combination with ofatumumab (Arzerra) compared to ofatumumab alone for previously treated CLL.
First Effective Adjuvant Treatment Identified in High-Risk Prostate Cancer
May 31st 2015, 5:00am
Treatment with an adjuvant combination of docetaxel, androgen deprivation therapy (ADT), and radiation therapy (RT) improved 4-year overall survival rates in patients with high-risk localized prostate cancer, when compared with ADT plus RT alone.
Obinutuzumab Doubles PFS in Refractory Indolent Non-Hodgkin Lymphoma
May 30th 2015, 3:35pm
Patients with relapsed indolent non-Hodgkin lymphoma experienced a doubling of progression-free survival when treated with a combination of the anti-CD20 agent obinutuzumab and bendamustine.
Dr. Chanan-Khan on Ibruitinib Combined with BR in CLL/SLL
May 30th 2015, 2:38pm
Asher A. Chanan-Khan, MD, chair, Hematology/Oncology, Cancer Center, Mayo Clinic, discusses a recent study that examined ibrutinib combined with bendamustine and ritxuimab (BR) in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Novel JAK Inhibitor Alleviates Key Myelofibrosis Symptoms
May 30th 2015, 1:51pm
Patients with myelofibrosis achieved significantly better outcomes in spleen volume reduction and symptom control with the novel JAK2 inhibitor pacritinib compared with best available therapy.
Daratumumab Data Impresses in Myeloma, FDA Submission Expected
May 30th 2015, 10:26am
Daratumumab demonstrated a 65% one-year overall survival rate and a 29.2% objective response rate in patients with double refractory heavily pretreated multiple myeloma.
Ibrutinib Regimen Improves PFS by 80% in Phase III CLL Study
May 30th 2015, 9:57am
Adding ibrutinib to standard bendamustine and rituximab (BR) reduced the risk of disease progression by 80% compared with BR plus placebo in patients with pretreated CLL or SLL.
Phase III Data Show Nivolumab Improves Survival Across Lung Cancer Subtypes
May 29th 2015, 3:59pm
Nivolumab has now been shown to have an overall survival benefit versus docetaxel in both nonsquamous and squamous non–small cell lung cancer.
Dr. Seiwert on Pembrolizumab in Head and Neck Cancer
May 29th 2015, 3:24pm
Tanguy Seiwert, MD, assistant professor of medicine and associate leader of the head and neck cancer program, University of Chicago, discusses the efficacy of pembrolizumab in head and neck cancer.
Study Opens Door for Nivolumab in HCC
May 29th 2015, 2:40pm
Nivolumab generated antitumor responses in nearly 20% of patients with advanced HCC in a small study that suggests a promising role for the immunotherapy agent in a malignancy with dismal outcomes.